Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
Journal article
Agustí A. et al, (2023), Respirology
A randomised trial of a T2-composite-biomarker strategy adjusting corticosteroidtreatment in severe asthma, a post- hoc analysis by sex.
Journal article
Eastwood MC. et al, (2023), The journal of allergy and clinical immunology. In practice
Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma.
Journal article
Pavord ID. et al, (2022), The journal of allergy and clinical immunology. In practice
Effectiveness of exhaled nitric oxide for the prediction of non-invasive left atrial pressure in older people: a cross-sectional cohort study
Journal article
Jones ST. et al, (2022), BJGP Open, BJGPO.2022.0105 - BJGPO.2022.0105
Diagnosis and assessment of the asthmas.
Journal article
Pavord ID. et al, (2022), The journal of allergy and clinical immunology. In practice
Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.
Journal article
Pavord ID., (2022), The European respiratory journal, 60
Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy
Journal article
Chen S. et al, (2022), International Journal of Chronic Obstructive Pulmonary Disease, Volume 17, 2187 - 2200
Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ ( FeNO ) framework
Journal article
Couillard S. et al, (2022), Respirology, 27, 573 - 577
Treatable traits in the NOVELTY study.
Journal article
Agustí A. et al, (2022), Respirology (Carlton, Vic.)
Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.
Journal article
Couillard S. et al, (2022), Thorax
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation.
Journal article
Diver S. et al, (2022), Allergy
Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker‐high and ‐low severe asthma
Journal article
Khalfaoui L. et al, (2022), Allergy
Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population.
Journal article
McDowell PJ. et al, (2022), American journal of respiratory and critical care medicine
Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling.
Journal article
Couillard S. et al, (2022), BMJ open, 12
Asthma remission- what is it and how can it be achieved?
Journal article
Thomas D. et al, (2022), The European respiratory journal
Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.
Journal article
Foster J. et al, (2022), BMJ open, 12
Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
Journal article
Couillard S. et al, (2022), ERJ Open Research, 00570 - 2021
Choosing a Biologic for Patients with Severe Asthma.
Journal article
Pavord ID. et al, (2021), The journal of allergy and clinical immunology. In practice
Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients
Journal article
Youngs J. et al, (2021), PLOS Pathogens, 17, e1009804 - e1009804
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil driven diseases
Journal article
Pavord ID. et al, (2021), Allergy